LB-102 compared with placebo for acute schizophrenia
About this title
Read the official source — NCT07363577Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
Adults aged 18–65 with an acute episode of schizophrenia may be eligible. This Phase 3 study randomly assigns participants to six weeks of LB-102 at 50 mg, LB-102 at 100 mg, or placebo (an inactive comparison treatment). Participants must be willing to stay in hospital for the study. Researchers are assessing the medicine against placebo; the study has not established its effects or safety.
- Listed locations
- Bentonville and 12 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 456
- Sponsor
- LB Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07363577
- Official title
Show the full official title
A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB 102 in the Treatment of Adult Patients With Acute Schizophrenia
Recruitment & locations
Bentonville · Little Rock · Culver City
9 more locations
- Garden Grove
- Lemon Grove
- Riverside
- Boynton Beach
- Miami Lakes
- Snellville
- Chicago
- St Louis
- North Canton
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is LB Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including LB-102 (50 mg tablet) and LB-102 (100 mg tablet).
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
